Literature DB >> 27306115

VITREOMACULAR ADHESION EVOLUTION WITH AGE IN HEALTHY HUMAN EYES.

Agustina C Palacio1, Akash Gupta, Brooke Lw Nesmith, Puja R Jadav, Yam Schaal, Shlomit Schaal.   

Abstract

PURPOSE: To quantify the changes in vitreomacular interactions that occur with normal aging in normal eyes.
METHODS: Spectral domain optical coherence tomography (SD-OCT, Spectralis; Heidelberg Engineering, Heidelberg, Germany) foveal scans of subjects with best corrected visual acuity better than 20/40 and no ocular pathology were included in the study. Each scan was analyzed to determine the status of vitreoretinal interface: complete vitreous adhesion, partial posterior vitreous detachment (PVD) with persistent vitreomacular adhesion (VMA), or complete PVD. Area of VMA was delineated using the Spectralis drawing tool and calculated in mm for each scan. Subjects, aged 10 years to 97 years, were divided into 9 age groups according to decade of life.
RESULTS: Five hundred and sixty-six SD-OCT scans were analyzed. Area of VMA (mm) decreased sigmoidally (R = 0.99) with each decade of life. With aging, percentage of PVD increased while percentage of complete adhesion decreased. Males were found to have significantly larger area of VMA (mm) compared with females in the fifth through eighth decades of life, P < 0.05.
CONCLUSION: Vitreomacular interface interactions throughout life are age and gender dependent. This adds to our current understanding of the normal aging process undergone by the vitreous, thereby providing assistance in the clinical differentiation between normal and pathologic vitreomacular interactions.

Entities:  

Mesh:

Year:  2017        PMID: 27306115     DOI: 10.1097/IAE.0000000000001115

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  8 in total

1.  The Charles Schepens Lecture: Management Options for Vitreomacular Traction: Use an Individualized Approach.

Authors:  Harry W Flynn; Nidhi Relhan
Journal:  Ophthalmol Retina       Date:  2017 Jan-Feb

2.  PNEUMATIC VITREOLYSIS FOR RELIEF OF VITREOMACULAR TRACTION.

Authors:  Clement K Chan; Jason N Crosson; Calvin E Mein; Noha Daher
Journal:  Retina       Date:  2017-10       Impact factor: 4.256

3.  Risk Factors for Residual Vitreous Cortex at the Fovea after Posterior Vitreous Detachment during Vitrectomy in Ocular Trauma.

Authors:  Anan Wang; Zhenquan Zhao; Qihua Xu; Yaohua Wang; Hongfei Liao
Journal:  J Ophthalmol       Date:  2019-07-28       Impact factor: 1.909

4.  Prevalence of Vitreoretinal Interface Disorders in an Australian Population: The Blue Mountains Eye Study.

Authors:  Gerald Liew; Helen Nguyen; I-Van Ho; Andrew J White; George Burlutsky; Bamini Gopinath; Paul Mitchell
Journal:  Ophthalmol Sci       Date:  2021-04-19

5.  PROGRESSION OF PARTIAL POSTERIOR VITREOUS DETACHMENT OVER TIME.

Authors:  Elizabeth C Koller; Jessica A Kraker; Eileen S Hwang
Journal:  Retina       Date:  2021-07-01       Impact factor: 3.975

6.  AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: The ARI2 Study.

Authors:  Rocio Blanco-Garavito; Camille Jung; Joel Uzzan; Maddalena Quaranta-ElMaftouhi; Florence Coscas; Jose Sahel; Jean-Francois Korobelnik; Stéphane Béchet; Giuseppe Querques; Eric H Souied
Journal:  Retina       Date:  2018-12       Impact factor: 4.256

7.  Continued smoking and posterior vitreous adhesion in the elderly evaluated on swept-source optical coherence tomography.

Authors:  Taku Toyama; Yohei Hashimoto; Hisashi Kawai; Kunihiro Azuma; Tomoyasu Shiraya; Fumiyuki Araki; Koichiro Sugimoto; Yutaka Watanabe; Hirohiko Hirano; Yoshinori Fujiwara; Kazushige Ihara; Hunkyung Kim; Satoshi Kato; Jiro Numaga; Shuichi Obuchi; Takashi Ueta
Journal:  Sci Rep       Date:  2020-10-28       Impact factor: 4.379

8.  Indications and outcomes for intravitreal injection of C3F8 gas for symptomatic vitreomacular traction.

Authors:  Josef Guber; Celine Rusch; Ivo Guber; Hendrik P N Scholl; Christophe Valmaggia
Journal:  Sci Rep       Date:  2021-09-10       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.